Literature DB >> 3570053

Randomized study of preoperative radiation and surgery or irradiation alone in the treatment of stage IB and IIA carcinoma of the uterine cervix: final report.

C A Perez, H M Camel, M S Kao, M A Hederman.   

Abstract

A prospective randomized study in selected patients with Stage IB and IIA carcinoma of the uterine cervix was carried out at Washington University between January 1966 and December 1979. Patients were randomized to be treated with irradiation alone consisting of 1000 cGy whole pelvis, additional 4000 cGy to the parametria with a step wedge midline block, and two intracavitary insertions for 7500 mgh; or irradiation and surgery, consisting of 2000 cGy whole pelvis irradiation, one intracavitary insertion for 5000-6000 mgh followed 2 to 6 weeks later by a radical hysterectomy with pelvic lymphadenectomy. A total of 40 patients with Stage IB and 16 with Stage IIA were randomized to be treated with irradiation alone. A similar group of 48 patients with Stage IB and 14 with IIA were randomized to the preoperative radiation and surgery group. The 5-year, tumor-free actuarial survival for Stage IB patients treated with radiation was 89% and with preoperative radiation and surgery 80%. In Stage IIA, the tumor-free actuarial 5-year survival was 56% for the irradiation alone group and 79% for the patients treated with preoperative radiation and radical hysterectomy. In the patients with Stage IB treated by irradiation alone only one pelvic failure combined with distant metastasis occurred, and 3 patients developed distant metastasis. In the 48 patients treated with combined therapy, there were six pelvic failures (12.5%) all combined with distant metastases and two distant metastases alone. In the 16 patients with Stage IIA treated with radiotherapy alone, there were four pelvic failures (all parametrial), three of them combined with distant metastasis. In the 14 patients treated with irradiation and surgery, two developed a pelvic recurrence, and one distant metastasis. In the preoperative radiation group, the incidence of metastatic pelvic lymph nodes was 6.3% in Stage IB and 7.1% in Stage IIA. Major complications of therapy in the patients treated with radiation alone (10%) consisted of one rectovaginal fistula, two vesicovaginal fistulas, and one rectal stricture. In the preoperative radiation group, three ureteral strictures and two severe proctitis-rectal strictures were noted (8%). The present study shows no significant difference in therapeutic results or morbidity for invasive carcinoma of the uterine cervix Stage IB or IIA treated with irradiation alone or combined with a radical hysterectomy and lymphadenectomy.

Entities:  

Mesh:

Year:  1987        PMID: 3570053     DOI: 10.1016/0090-8258(87)90285-x

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  10 in total

1.  Urological complications after radical hysterectomy with or without radiotherapy for cervical cancer.

Authors:  G Ralph; K Tamussino; W Lichtenegger
Journal:  Arch Gynecol Obstet       Date:  1990       Impact factor: 2.344

2.  Clinical efficacy of nedaplatin-based concurrent chemoradiotherapy for uterine cervical cancer: a Tohoku Gynecologic Cancer Unit Study.

Authors:  Masahiro Kagabu; Tadahiro Shoji; Kazuyuki Murakami; Hideo Omi; Tatsuya Honda; Fumiharu Miura; Yoshihito Yokoyama; Hideki Tokunaga; Tadao Takano; Tsuyoshi Ohta; Dai Shimizu; Naoki Sato; Shu Soeda; Takafumi Watanabe; Hidekazu Yamada; Hideki Mizunuma; Nobuo Yaegashi; Satoru Nagase; Toru Tase; Toru Sugiyama
Journal:  Int J Clin Oncol       Date:  2016-01-19       Impact factor: 3.402

Review 3.  Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer.

Authors:  Fani Kokka; Andrew Bryant; Adeola Olaitan; Elly Brockbank; Melanie Powell; David Oram
Journal:  Cochrane Database Syst Rev       Date:  2022-08-22

Review 4.  Debulking hysterectomy followed by chemoradiotherapy versus chemoradiotherapy for FIGO stage (2019) IB3/II cervical cancer.

Authors:  Manas Chakrabarti; Andy Nordin; Juneida Khodabocus
Journal:  Cochrane Database Syst Rev       Date:  2022-09-16

5.  Feasibility and effectiveness of postoperative adjuvant concurrent chemoradiation therapy in Japanese patients with high-risk early-stage cancer of the uterine cervix.

Authors:  Kiyosumi Shibata; Hiroaki Kajiyama; Mikio Terauchi; Eiko Yamamoto; Kazuhiko Ino; Akihiro Nawa; Fumitaka Kikkawa
Journal:  Int J Clin Oncol       Date:  2008-06-14       Impact factor: 3.402

6.  Preoperative external beam radiotherapy and reduced dose brachytherapy for carcinoma of the cervix: survival and pathological response.

Authors:  Alexandre A Jacinto; Marcus S Castilho; Paulo E R S Novaes; Pablo R Novick; Gustavo A Viani; João V Salvajoli; Robson Ferrigno; Antonio Cássio A Pellizzon; Stella S S Lima; Maria A C Maia; Ricardo C Fogaroli
Journal:  Radiat Oncol       Date:  2007-02-22       Impact factor: 3.481

7.  Clinical outcomes of adjuvant radiation therapy and prognostic factors in early stage uterine cervical cancer.

Authors:  Hyun Ju Kim; Woo Joong Rhee; Seo Hee Choi; Eun Ji Nam; Sang Wun Kim; Sunghoon Kim; Young Tae Kim; Gwi Eon Kim; Yong Bae Kim
Journal:  Radiat Oncol J       Date:  2015-06-30

8.  Incorporation of the number of positive lymph nodes leads to better prognostic discrimination of node-positive early stage cervical cancer.

Authors:  Juan Zhou; San-Gang Wu; Jia-Yuan Sun; Xu-Lin Liao; Feng-Yan Li; Huan-Xin Lin; Li-Chao Yang; Zhen-Yu He
Journal:  Oncotarget       Date:  2017-04-18

9.  Neoadjuvant and Adjuvant Treatments Compared to Concurrent Chemoradiotherapy for Patients With Locally Advanced Cervical Cancer: A Bayesian Network Meta-Analysis.

Authors:  Yunfeng Qiao; Huijun Li; Bing Peng
Journal:  Front Oncol       Date:  2022-03-16       Impact factor: 6.244

10.  Adjuvant hysterectomy for treatment of residual disease in patients with cervical cancer treated with radiation therapy.

Authors:  T Ota; N Takeshima; T Tabata; K Hasumi; K Takizawa
Journal:  Br J Cancer       Date:  2008-10-21       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.